Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab (Mar, 10.1080/08923973.2023.2183352, 2023)-MedSci.cn

Evaluation of HER-2 positive breast cancer treated with dual-targeted treatment of trastuzumab plus pertuzumab (Mar, 10.1080/08923973.2023.2183352, 2023)

Jiang, S; Geng, S; Gao, X; Liu, T; Luo, X; Wang, N; Shi, N; Dong, M

IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY, 2023; 45 (5): I

科室
- - 订阅+
  - 更多科室
工具
服务